Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector
AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved treatments.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 86,933 | $16,136,503 | -3% | 6.91% |
| 2. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,923 | $356,947 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing | |
| $212.34 | 17,644 | $3,746,526.96 | 11,577 | 2025-03-14 | Filing | |
| $210.53 | 6,168 | $1,298,549.04 | 388,929 | 2025-03-03 | Filing | |
| $205.11 | 92,460 | $18,964,470.60 | 395,097 | 2025-02-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,332,054 | $804,115,863 | 1.19% | |
| 2. | 1,922,679 | $356,887,678 | 0.4% | |
| 3. | 1,454,878 | $270,054,454 | 0.93% | |
| 4. | 1,048,600 | $194,588,702 | 0.91% | |
| 5. | 736,329 | $136,677,389 | 0.46% |
News See All
14 Best Pharma Dividend Stocks to Buy in 2025
The US pharmaceutical industry has undergone notable shifts in recent years, influenced by factors such as the COVID-19 pandemic, expanded collaborations across the value chain, and ongoing changes in...
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating
AbbVie Inc. (NYSE:ABBV) is one of the high-margin pharma stocks to buy now. AbbVie Inc.
13 Best Long Term Low Volatility Stocks to Buy Now
On July 15, James Bianco, Bianco Research president, appeared on CNBC's 'Closing Bell Overtime' to discuss the latest inflation read and why he believes that a rate cut by the Federal Reserve could be...
10 Best High-Margin Pharma Stocks to Buy Now
The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global economic uncertainty.
AbbVie (ABBV) Strengthens Pays $700M to Strengthen Oncology Portfolio with ISB 2001
AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the confirmation of an exclusive licensing deal with IGI Therapeutics.
Goldman Sachs Healthcare Stocks: Top 10 Stock Picks
The healthcare sector has been under pressure, underperforming the S&P 500 over the past several years.
AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense
AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts.
7 Most Undervalued Pot Stocks To Buy According To Analysts
The global cannabis market was worth $26.86 billion in 2022, Spherical Insights & Consulting data shows. Three years later, Mordor Intelligence valued the market at $44.60 billion.
AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV.
Billionaire Hedge Funds
